ADC Therapeutics SA
NYSE:ADCT
Income Statement
Earnings Waterfall
ADC Therapeutics SA
Revenue
|
69.6m
USD
|
Cost of Revenue
|
-2.5m
USD
|
Gross Profit
|
67m
USD
|
Operating Expenses
|
-233m
USD
|
Operating Income
|
-166m
USD
|
Other Expenses
|
-74.1m
USD
|
Net Income
|
-240.1m
USD
|
Income Statement
ADC Therapeutics SA
Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||
Revenue |
2
N/A
|
2
-15%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
4
N/A
|
17
+350%
|
34
+100%
|
80
+137%
|
94
+17%
|
157
+67%
|
210
+34%
|
182
-13%
|
184
+1%
|
123
-34%
|
70
-43%
|
|
Gross Profit | ||||||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
4
N/A
|
16
+348%
|
33
+100%
|
79
+142%
|
92
+17%
|
155
+69%
|
208
+34%
|
180
-13%
|
182
+1%
|
121
-34%
|
67
-44%
|
|
Operating Income | ||||||||||||||||||
Operating Expenses |
(122)
|
(138)
|
(157)
|
(177)
|
(219)
|
(246)
|
(282)
|
(300)
|
(302)
|
(318)
|
(322)
|
(329)
|
(329)
|
(311)
|
(285)
|
(257)
|
(233)
|
|
Selling, General & Administrative |
(14)
|
(20)
|
(35)
|
(53)
|
(93)
|
(100)
|
(116)
|
(129)
|
(136)
|
(142)
|
(143)
|
(146)
|
(141)
|
(151)
|
(141)
|
(128)
|
(106)
|
|
Research & Development |
(106)
|
(118)
|
(122)
|
(124)
|
(140)
|
(146)
|
(165)
|
(170)
|
(164)
|
(175)
|
(177)
|
(182)
|
(186)
|
(176)
|
(160)
|
(145)
|
(127)
|
|
Depreciation & Amortization |
(2)
|
0
|
0
|
0
|
(2)
|
(0)
|
(1)
|
(1)
|
(3)
|
(2)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(2)
|
0
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
16
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
18
|
18
|
18
|
0
|
|
Operating Income |
(119)
N/A
|
(136)
-14%
|
(157)
-15%
|
(177)
-12%
|
(219)
-24%
|
(246)
-12%
|
(278)
-13%
|
(284)
-2%
|
(270)
+5%
|
(240)
+11%
|
(230)
+4%
|
(174)
+24%
|
(121)
+31%
|
(131)
-8%
|
(103)
+21%
|
(137)
-33%
|
(166)
-21%
|
|
Pre-Tax Income | ||||||||||||||||||
Interest Income Expense |
2
|
2
|
(79)
|
(47)
|
(26)
|
(7)
|
71
|
26
|
10
|
13
|
19
|
24
|
8
|
(23)
|
(42)
|
(44)
|
(35)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
7
|
7
|
8
|
8
|
(1)
|
(41)
|
(42)
|
(43)
|
(41)
|
(2)
|
0
|
|
Total Other Income |
2
|
2
|
0
|
(1)
|
(1)
|
(1)
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
6
|
|
Pre-Tax Income |
(116)
N/A
|
(133)
-15%
|
(236)
-78%
|
(225)
+5%
|
(246)
-9%
|
(254)
-3%
|
(200)
+21%
|
(251)
-26%
|
(252)
0%
|
(218)
+13%
|
(211)
+3%
|
(191)
+10%
|
(155)
+19%
|
(197)
-27%
|
(185)
+6%
|
(182)
+2%
|
(195)
-8%
|
|
Net Income | ||||||||||||||||||
Tax Provision |
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
22
|
23
|
24
|
25
|
(1)
|
(2)
|
4
|
3
|
(39)
|
|
Income from Continuing Operations |
(117)
|
(133)
|
(237)
|
(226)
|
(246)
|
(254)
|
(200)
|
(252)
|
(230)
|
(195)
|
(187)
|
(166)
|
(156)
|
(199)
|
(181)
|
(179)
|
(235)
|
|
Equity Earnings Affiliates |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(6)
|
|
Net Income (Common) |
(117)
N/A
|
(133)
-15%
|
(237)
-77%
|
(226)
+5%
|
(246)
-9%
|
(254)
-3%
|
(200)
+21%
|
(252)
-26%
|
(230)
+9%
|
(195)
+15%
|
(187)
+4%
|
(166)
+11%
|
(156)
+6%
|
(199)
-27%
|
(181)
+9%
|
(179)
+2%
|
(240)
-34%
|
|
EPS (Diluted) |
-1.52
N/A
|
-1.88
-24%
|
-3.34
-78%
|
-2.94
+12%
|
-3.21
-9%
|
-3.31
-3%
|
-2.61
+21%
|
-3.28
-26%
|
-3
+9%
|
-2.55
+15%
|
-2.44
+4%
|
-2.11
+14%
|
-1.99
+6%
|
-2.45
-23%
|
-2.22
+9%
|
-2.17
+2%
|
-2.94
-35%
|